Sanofi Us Services Drug Patent Portfolio
Sanofi Us Services owns 2 orange book drugs protected by 21 US patents Given below is the list of Sanofi Us Services's drug patents along with their expiration dates.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US10369291 | Mechanism for a drug delivery device | 16 Sep, 2035 | Active |
US9345750 | Long-acting formulations of insulin | 18 May, 2031 | Active |
US7918833 | Pen-type injector | 23 Mar, 2028 | Active |
US7918833 | Pen-type injector | 23 Sep, 2027 | Active |
US8679069 | Pen-type injector | 12 Apr, 2025 | Active |
US8512297 | Pen-type injector | 15 Sep, 2024 | Expired |
US9561331 | Drive mechanisms suitable for use in drug delivery devices | 28 Aug, 2024 | Expired |
US9623189 | Relating to drive mechanisms suitable for use in drug delivery devices | 19 Aug, 2024 | Expired |
US9533105 | Drive mechanisms suitable for use in drug delivery devices | 17 Aug, 2024 | Expired |
US9604009 | Drive mechanisms suitable for use in drug delivery devices | 16 Aug, 2024 | Expired |
US8992486 | Pen-type injector | 05 Jun, 2024 | Expired |
US9011391 | Pen-type injector | 26 Mar, 2024 | Expired |
US8556864 | Drive mechanisms suitable for use in drug delivery devices | 03 Mar, 2024 | Expired |
US8603044 | Pen-type injector | 02 Mar, 2024 | Expired |
US9233211 | Relating to a pen-type injector | 02 Mar, 2024 | Expired |
US9408979 | Pen-type injector | 02 Mar, 2024 | Expired |
US9526844 | Pen-type injector | 02 Mar, 2024 | Expired |
US9604008 | Drive mechanisms suitable for use in drug delivery devices | 02 Mar, 2024 | Expired |
US9610409 | Drive mechanisms suitable for use in drug delivery devices | 02 Mar, 2024 | Expired |
US9775954 | Pen-type injector | 02 Mar, 2024 | Expired |
US9827379 | Drive mechanisms suitable for use in drug delivery devices | 02 Mar, 2024 | Expired |
Latest Legal Activities on Sanofi Us Services's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Sanofi Us Services.
Activity | Date | Patent Number |
---|---|---|
Payment of Maintenance Fee, 8th Year, Large Entity | 08 Nov, 2023 | US9345750 |
Payment of Maintenance Fee, 8th Year, Large Entity | 08 Nov, 2023 | US9345750 |
Payment of Maintenance Fee, 4th Year, Large Entity | 25 Jan, 2023 | US10369291 |
Payment of Maintenance Fee, 4th Year, Large Entity | 25 Jan, 2023 | US10369291 |
Post Issue Communication - Certificate of Correction | 13 Nov, 2019 | US10369291 |
Post Issue Communication - Certificate of Correction | 13 Nov, 2019 | US10369291 |
Payment of Maintenance Fee, 4th Year, Large Entity | 08 Nov, 2019 | US9345750 |
Payment of Maintenance Fee, 4th Year, Large Entity | 08 Nov, 2019 | US9345750 |
Recordation of Patent Grant Mailed
Critical
| 06 Aug, 2019 | US10369291 |
Recordation of Patent Grant Mailed
Critical
| 06 Aug, 2019 | US10369291 |
Patent Issue Date Used in PTA Calculation
Critical
| 06 Aug, 2019 | US10369291 |
Patent Issue Date Used in PTA Calculation
Critical
| 06 Aug, 2019 | US10369291 |
Email Notification
Critical
| 18 Jul, 2019 | US10369291 |
Email Notification
Critical
| 18 Jul, 2019 | US10369291 |
Issue Notification Mailed
Critical
| 17 Jul, 2019 | US10369291 |
Sanofi Us Services's Drug Patent Litigations
Sanofi Us Services's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Sep 10, 2018, against patent number US8992486. The petitioner Mylan Pharmaceuticals Inc et al., challenged the validity of this patent, with Sanofi-Aventis Deutschland GmbH et al. as the respondent. Click below to track the latest information on how companies are challenging Sanofi Us Services's patents.
Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
---|---|---|---|---|
US8679069 | May, 2019 |
FWD Entered
(11 Aug, 2020)
| Sanofi-Aventis Deutschland | Pfizer Inc. |
US8603044 | September, 2018 |
FWD Entered
(29 May, 2020)
| Sanofi-Aventis Deutschland GmbH | Mylan Pharmaceuticals Inc. |
US8992486 | September, 2018 |
FWD Entered
(29 May, 2020)
| Sanofi-Aventis Deutschland GmbH | Mylan Pharmaceuticals Inc. |
US8992486 | October, 2018 |
FWD Entered
(29 May, 2020)
| Sanofi-Aventis Deutschland GmbH | Mylan Pharmaceuticals Inc. |
US9526844 | September, 2018 |
FWD Entered
(29 May, 2020)
| Sanofi-Aventis Deutschland GmbH | Mylan Pharmaceuticals Inc |
US9526844 | September, 2018 |
FWD Entered
(29 May, 2020)
| Sanofi-Aventis Deutschland GmbH | Mylan Pharmaceuticals Inc. |
US9604008 | September, 2018 |
FWD Entered
(29 May, 2020)
| Sanofi-Aventis Deutschland GmbH | Mylan Pharmaceuticals Inc. |
US8679069 | September, 2018 |
FWD Entered
(02 Apr, 2020)
| Sanofi-Aventis Deutshland GmbH | Mylan Pharmaceuticals Inc. |
US9526844 | May, 2019 |
Terminated-Other
(20 Aug, 2019)
| Sanofi-Aventis Deutschland | Pfizer Inc. |
US9526844 | May, 2019 |
Terminated-Other
(19 Aug, 2019)
| Sanofi-Aventis Deutschland | Pfizer Inc. |
US8603044 | May, 2019 |
Terminated-Other
(15 Aug, 2019)
| Sanofi-Aventis Deutschland | Pfizer Inc. |
US8992486 | May, 2019 |
Terminated-Other
(15 Aug, 2019)
| Sanofi-Aventis Deutschland | Pfizer Inc. |
US9604008 | May, 2019 |
Terminated-Other
(15 Aug, 2019)
| Sanofi-Aventis Deutschland | Pfizer Inc. |
US9526844 | September, 2018 |
Terminated-Denied
(03 Apr, 2019)
| Sanofi-Aventis Deutschland GmbH | Mylan Pharmaceuticals Inc. |
US8992486 | September, 2018 |
Terminated
(19 Dec, 2018)
| Sanofi-Aventis Deutschland GmbH et al. | Mylan Pharmaceuticals Inc et al. |
Sanofi Us Services's Family Patents
Sanofi Us Services Drug List
Given below is the complete list of Sanofi Us Services's drugs and the patents protecting them.
1. Toujeo Max Solostar
Toujeo Max Solostar is protected by 20 patents, out of which 16 have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US10369291 | Mechanism for a drug delivery device |
16 Sep, 2035
(10 years from now)
| Active |
US9345750 | Long-acting formulations of insulin |
18 May, 2031
(6 years from now)
| Active |
US7918833 | Pen-type injector |
23 Sep, 2027
(2 years from now)
| Active |
US8679069 | Pen-type injector |
12 Apr, 2025
(4 months from now)
| Active |
US8512297 | Pen-type injector |
15 Sep, 2024
(2 months ago)
| Expired |
US9561331 | Drive mechanisms suitable for use in drug delivery devices |
28 Aug, 2024
(3 months ago)
| Expired |
US9623189 | Relating to drive mechanisms suitable for use in drug delivery devices |
19 Aug, 2024
(3 months ago)
| Expired |
US9533105 | Drive mechanisms suitable for use in drug delivery devices |
17 Aug, 2024
(3 months ago)
| Expired |
US9604009 | Drive mechanisms suitable for use in drug delivery devices |
16 Aug, 2024
(3 months ago)
| Expired |
US8992486 | Pen-type injector |
05 Jun, 2024
(6 months ago)
| Expired |
US9011391 | Pen-type injector |
26 Mar, 2024
(8 months ago)
| Expired |
US8556864 | Drive mechanisms suitable for use in drug delivery devices |
03 Mar, 2024
(9 months ago)
| Expired |
US8603044 | Pen-type injector |
02 Mar, 2024
(9 months ago)
| Expired |
US9233211 | Relating to a pen-type injector |
02 Mar, 2024
(9 months ago)
| Expired |
US9408979 | Pen-type injector |
02 Mar, 2024
(9 months ago)
| Expired |
US9526844 | Pen-type injector |
02 Mar, 2024
(9 months ago)
| Expired |
US9604008 | Drive mechanisms suitable for use in drug delivery devices |
02 Mar, 2024
(9 months ago)
| Expired |
US9610409 | Drive mechanisms suitable for use in drug delivery devices |
02 Mar, 2024
(9 months ago)
| Expired |
US9775954 | Pen-type injector |
02 Mar, 2024
(9 months ago)
| Expired |
US9827379 | Drive mechanisms suitable for use in drug delivery devices |
02 Mar, 2024
(9 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Toujeo Max Solostar's drug page
2. Toujeo Solostar
Toujeo Solostar is protected by 21 patents, out of which 16 have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US10369291 | Mechanism for a drug delivery device |
16 Sep, 2035
(10 years from now)
| Active |
US9345750 | Long-acting formulations of insulin |
18 May, 2031
(6 years from now)
| Active |
US7918833
(Pediatric)
| Pen-type injector |
23 Mar, 2028
(3 years from now)
| Active |
US7918833 | Pen-type injector |
23 Sep, 2027
(2 years from now)
| Active |
US8679069 | Pen-type injector |
12 Apr, 2025
(4 months from now)
| Active |
US8512297 | Pen-type injector |
15 Sep, 2024
(2 months ago)
| Expired |
US9561331 | Drive mechanisms suitable for use in drug delivery devices |
28 Aug, 2024
(3 months ago)
| Expired |
US9623189 | Relating to drive mechanisms suitable for use in drug delivery devices |
19 Aug, 2024
(3 months ago)
| Expired |
US9533105 | Drive mechanisms suitable for use in drug delivery devices |
17 Aug, 2024
(3 months ago)
| Expired |
US9604009 | Drive mechanisms suitable for use in drug delivery devices |
16 Aug, 2024
(3 months ago)
| Expired |
US8992486 | Pen-type injector |
05 Jun, 2024
(6 months ago)
| Expired |
US9011391 | Pen-type injector |
26 Mar, 2024
(8 months ago)
| Expired |
US8556864 | Drive mechanisms suitable for use in drug delivery devices |
03 Mar, 2024
(9 months ago)
| Expired |
US8603044 | Pen-type injector |
02 Mar, 2024
(9 months ago)
| Expired |
US9233211 | Relating to a pen-type injector |
02 Mar, 2024
(9 months ago)
| Expired |
US9408979 | Pen-type injector |
02 Mar, 2024
(9 months ago)
| Expired |
US9526844 | Pen-type injector |
02 Mar, 2024
(9 months ago)
| Expired |
US9604008 | Drive mechanisms suitable for use in drug delivery devices |
02 Mar, 2024
(9 months ago)
| Expired |
US9610409 | Drive mechanisms suitable for use in drug delivery devices |
02 Mar, 2024
(9 months ago)
| Expired |
US9775954 | Pen-type injector |
02 Mar, 2024
(9 months ago)
| Expired |
US9827379 | Drive mechanisms suitable for use in drug delivery devices |
02 Mar, 2024
(9 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Toujeo Solostar's drug page